Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer [CRISPR]

ABSTRACT: Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer [CRISPR]

PROVIDER: PRJNA705890 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13825861.fastq.gz	Fastqsanger.gz
	SRR13825862.fastq.gz	Fastqsanger.gz
	SRR13825863.fastq.gz	Fastqsanger.gz
	SRR13825864.fastq.gz	Fastqsanger.gz
	SRR13825865.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer [RNA_seq]

Project description:A subset of triple negative breast cancers (TNBC) are characterized by genetic alterations in fibroblast growth factor receptors (FGFR) including amplifications, activating mutations or gene fusions. However, despite this genetic evidence of FGFR-dependency, FGFR inhibitors have shown only limited clinical efficacy in TNBC, suggesting the presence of intrinsic or adaptive resistance mechanisms. Using genome-wide CRISPR screens, we found that resistance to FGFR inhibition is mediated by activation of the mTORC1 and YAP pathways. Prolonged FGFR inhibition increased expression of several amino acid transporters resulting in increased cellular level of certain amino acids and activation of the mTORC1 amino acid sensing pathway. Epigenomic analyses revealed that FGFR inhibition reorganized YAP/TEAD associated enhancers leading to the upregulation of YAP target genes including the amino acid transporters upstream of mTORC1. Remarkably, mTORC1 and FGFR inhibitors synergistically blocked the growth of TNBC cells in vitro and in patient-derived xenografts. These findings define a novel epigenetic feedback mechanism involving intracellular amino acid levels leading to targeted therapy resistance in TNBC, and offers a combinatorial drug treatment strategy to improve clinical outcomes for this aggressive breast cancer subtype.

2021-09-09 | GSE168023 | GEO